News

TB R&D Weekly Update: Podcast Interview with Dr. Edward Nardell

Dr. Edward Nardell, Partners in Health
Dr. Edward Nardell, Partners in Health

Listen to Edward Nardell Podcast

Summary: This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis; trained in pulmonary medicine at Massachusetts General Hospital with additional research training at Boston University School of Medicine. His principal academic appointment is as associate professor of medicine, Harvard Medical School, with secondary parallel appointments in the Department of Global Health and Social Medicine and Harvard School of Public Health. In 2002 he joined Partners In Health as Director of Tuberculosis Research.

His research interests include the control of multidrug-resistant tuberculosis (MDR-TB) in Peru, Russia, and other high-burden countries, with a special research interest in airborne TB transmission and control. Dr. Nardell is currently conducting a research project in South Africa studying the transmission of MDR-TB using large numbers of guinea pigs to quantify the infectiousness of MDR-TB patients and the effectiveness of various control interventions, including ultraviolet germicidal irradiation. (Click here to view full bio) During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.

Additional TB R&D News:

CDC: Latent TB treatment may now be done in 3 months

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

New Findings Reported from Georgia Institute of Technology Describe Advances in Microbial Drug Resistance

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...